Renal Cancer - Results from #580

Functional recovery after partial nephrectomy in a solitary kidney. December 28, 2023

Early Evolution in Cancer: A Mathematical Support for Pathological and Genomic Evidence in Clear Cell Renal Cell Carcinoma. December 27, 2023

Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinoma. December 27, 2023

Correlation between bilateral GFR in patients with localized renal cancer after partial nephrectomy. December 26, 2023

Long-Term Survival of Patients with Stage T1N0M1 Renal Cell Carcinoma. December 26, 2023

Genomic Evolution of Oligometastatic Clear Cell Renal Cell Carcinoma Presenting Two Decades Following Radical Nephrectomy. December 25, 2023

Pathogenic Germline Mutational Landscape in Patients With Renal Cell Carcinoma and Associated Clinicopathologic Features. December 25, 2023

Lithographically defined encoded magnetic heterostructures for the targeted screening of kidney cancer. December 22, 2023

A Literature Review of Perioperative Outcomes of Robotic Radical Nephrectomy (RRN) Versus Laparoscopic Radical Nephrectomy (LRN) for Renal Cell Carcinoma (RCC). December 22, 2023

The evolution of PET imaging in renal, bladder, upper urinary tract urothelial, testicular and penile carcinoma - Today's impact, tomorrow's potential. December 21, 2023

Multimodal deep learning for personalized renal cell carcinoma prognosis: Integrating CT imaging and clinical data. December 21, 2023

Diversity in Renal Mass Data Cohorts: Implications for Urology AI Researchers. December 20, 2023

Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART). December 20, 2023

Real-World Treatment Patterns and Effectiveness of Patients With Advanced Renal Cell Carcinoma: A Nationwide Observational Study. December 19, 2023

Molecular Characterization of TFE3-rearranged Renal Cell Carcinoma, A Comparative Study with Papillary and Clear Cell Renal Cell Carcinomas. December 19, 2023

Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence. December 18, 2023

Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. December 18, 2023

FDA Approves Merck’s WELIREG® (Belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI December 16, 2023

PD-1 Expression on Intratumoral Regulatory T Cells is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear Cell Renal Cell Carcinoma Patients. December 15, 2023

Downregulation of Glycine N-Acyltransferase in Kidney Renal Clear Cell Carcinoma: A Bioinformatic-Based Screening. December 15, 2023

Page 30 of 456